Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) have been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and fourteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $247.20.
ALNY has been the topic of several research reports. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $205.00 to $210.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 4th. BMO Capital Markets raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $200.00 to $250.00 in a research report on Friday, May 5th. Sanford C. Bernstein started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 21st. They issued an “outperform” rating and a $243.00 target price for the company. Sumitomo Mitsui Financial Group started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 26th. They issued a “neutral” rating and a $220.00 target price for the company. Finally, 92 Resources restated an “initiates” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 26th.
Insider Buying and Selling at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, EVP Indrani Lall Franchini sold 3,500 shares of the firm’s stock in a transaction dated Thursday, April 6th. The shares were sold at an average price of $210.00, for a total transaction of $735,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Indrani Lall Franchini sold 3,500 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, April 6th. The shares were sold at an average price of $210.00, for a total transaction of $735,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $1,481,802.85. Following the sale, the chief executive officer now owns 30,332 shares of the company’s stock, valued at $5,902,303.88. The disclosure for this sale can be found here. In the last three months, insiders sold 17,799 shares of company stock worth $3,517,442. 1.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Raymond James Financial Services Advisors Inc. grew its holdings in Alnylam Pharmaceuticals by 9.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock valued at $1,935,000 after purchasing an additional 1,017 shares during the period. MetLife Investment Management LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at approximately $1,268,000. Panagora Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 96.4% in the first quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares during the period. Great West Life Assurance Co. Can grew its holdings in Alnylam Pharmaceuticals by 21.2% in the first quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 10,892 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Alnylam Pharmaceuticals by 1.2% in the first quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares during the period. 94.43% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Price Performance
NASDAQ ALNY opened at $189.69 on Wednesday. The firm’s fifty day moving average price is $196.14 and its 200 day moving average price is $207.15. The company has a market capitalization of $23.62 billion, a price-to-earnings ratio of -21.83 and a beta of 0.48. Alnylam Pharmaceuticals has a 12 month low of $135.46 and a 12 month high of $242.97.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) last issued its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.97) by $0.57. Alnylam Pharmaceuticals had a negative net margin of 93.13% and a negative return on equity of 1,287.80%. The company had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. During the same period last year, the firm posted ($2.00) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 49.7% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals will post -6.52 earnings per share for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alnylam Pharmaceuticals wasn’t on the list.
While Alnylam Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
